HIV-1 Genotyping Assay for Non-B Subtype Surveillance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 genotyping assays are inadequate for non-B subtypes and circulating recombinant forms prevalent in resource-limited settings, as they are expensive, less sensitive, and do not cover the entire protease gene region, leading to incomplete genotyping and detection challenges.
Innovation Solution
Development of specific nucleic acid primers that can genotype HIV-1 M subtypes, including non-B subtypes and CRFs, using RT-PCR and nested PCR to amplify and sequence the pol gene region, providing high sensitivity and specificity for detecting drug-resistant mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If commercial genotyping assays (ViroSeq, TRUGENE) are used, then genotyping can be performed with standardized protocols, but they are expensive and less sensitive to non-B subtypes
Solution Approach 1:
The patent designs subtype-specific primers tailored to different HIV-1 subtypes (A, B, C, D, F, G, H, J, K and CRFs). Each primer set is optimized for its target subtype's genetic characteristics, ensuring high sensitivity and specificity for each regional variant while maintaining standardized assay protocols.
Solution Approach 2:
The patent creates a universal genotyping system that can detect multiple HIV-1 subtypes through a panel of primers. The assay framework is designed to accommodate different subtype-specific primers, allowing a single laboratory platform to serve diverse epidemiological contexts without requiring separate specialized systems for each subtype.
2Ease of manufacture
If original in-house assay is used, then cost is reduced, but it does not cover the entire PR gene region and generates background noise
Solution Approach 1:
The patent divides the protease gene region into multiple amplicons covered by different primer sets. The complete PR gene coverage is achieved by combining results from multiple segmented PCR reactions, ensuring all potential drug resistance mutations are detected while maintaining cost-effective in-house assay procedures.
Solution Approach 2:
The patent optimizes primer sequences and PCR conditions to minimize background noise while maximizing signal specificity. By adjusting primer design parameters (sequence composition, binding temperature, annealing conditions), the assay achieves high sensitivity for detecting minority variants without the background interference that plagues earlier in-house methods.
3Measurement precision
If assays designed for subtype B are used, then they work well for predominant strains in resource-rich countries, but they are inadequate for non-B subtypes prevalent in resource-limited settings
Solution Approach 1:
The patent develops region-specific primer sets matched to the predominant HIV-1 subtypes in different geographical areas. Primers are designed based on the genetic characteristics of locally circulating strains, ensuring optimal detection sensitivity for each region's epidemic profile while maintaining a unified global surveillance framework.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a high sensitivity of 95.8% and specificity of 99.3% in detecting HIV-1 drug-resistant mutations, outperforming existing assays and allowing for accurate genotyping of diverse HIV-1 strains, including those in resource-limited settings, with potential cost savings.
Implementation Method 1
contacting a sample obtained from a subject with a first forward nucleic acid primer... and a first reverse nucleic acid primer... thereby generating a first reaction mixture
Implementation Method 2
The first reaction mixture is subjected to conditions that permit amplification of a portion of HIV-1 pol in the sample... thereby generating a first amplification product
Data Source
Figure 1
Figure 2A~2C
Figure 3A~3B
AI summary
Provided herein are new methods, primers, and kits for genotyping HIV-1, including group M viral strains. The methods can be used for HIV-1 drug resistance surveillance and monitoring, for example in resource-poor countries. The disclosed methods can detected more mixed HIV-1 population than previous methods. Given the high efficiency in genotyping diverse HIV-1 group M viral strains from plasma and dried blood spot (DBS) samples and substantial reagent cost saving, the disclosed methods can be used for HIV-1 drug resistance genotyping in both antiretroviral therapy (ART)-naive and -experienced populations for surveillance purposes and patient monitoring.